Holen Sie sich die Stockscreener-App
3.16
4.82%
-0.16
C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten
Aug Intraday: Is C4 Therapeutics Inc currently under institutional pressureJuly 2025 Snapshot & Technical Confirmation Trade Alerts - khodrobank.com
C4 Therapeutics’ myeloma drug shows 50% response rate in trial - Investing.com
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting - The Manila Times
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple - GlobeNewswire
50% Response Rate: C4T's New Multiple Myeloma Drug Shows Promise with 9.3-Month Duration - Stock Titan
Dividend Watch: Whats the MACD signal for C4 Therapeutics Inc2025 Big Picture & Long Hold Capital Preservation Plans - khodrobank.com
C4 Therapeutics (NASDAQ:CCCC) Raised to "Overweight" at Stephens - MarketBeat
C4 Therapeutics (NASDAQ:CCCC) Now Covered by Analysts at Barclays - MarketBeat
Performance Recap: Can C4 Therapeutics Inc reach resistance levels soonMarket Volume Report & Safe Entry Trade Reports - khodrobank.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
202,000 Shares at $1.20: Tenaya Therapeutics Grants Inducement Stock Options to New Employees - Stock Titan
C4 Therapeutics (NASDAQ:CCCC) Coverage Initiated at Barclays - MarketBeat
C4 Therapeutics (CCCC): Evaluating Valuation After Analyst Upgrade and Pipeline Developments - Yahoo Finance
697,653 Shares in C4 Therapeutics, Inc. $CCCC Acquired by Jacobs Levy Equity Management Inc. - MarketBeat
Analyst Barclays Initiates Coverage on C4 Therapeutics (CCCC) wi - GuruFocus
Barclays Initiates Coverage of C4 Therapeutics (CCCC) with Overweight Recommendation - Nasdaq
Portfolio Update: Will C4 Therapeutics Inc. benefit from current market trends2025 Retail Activity & Smart Allocation Stock Tips - خودرو بانک
Momentum Shift: Will C4 Therapeutics Inc stock benefit from M APortfolio Update Summary & Technical Buy Zone Confirmation - khodrobank.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully - 富途牛牛
Does FDA Progress Reinforce C4 Therapeutics' (CCCC) Platform Validation Story in Autoimmune Disease? - Yahoo Finance
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Surprises Report: Will C4 Therapeutics Inc outperform during market ralliesEarnings Overview Report & Long-Term Investment Growth Plans - khodrobank.com
Why C4 Therapeutics Stock Crushed the Market on Monday - Yahoo Finance
Risk Hedge: Should I set a stop loss on Reservoir Media Inc. Equity WarrantWeekly Trend Recap & Detailed Earnings Play Strategies - خودرو بانک
Aug Reactions: Is C4 Therapeutics Inc a good ESG investmentJuly 2025 Snapshot & Safe Swing Trade Setups - khodrobank.com
Valuation Update: Does RSVR have consistent dividend growthWeekly Profit Recap & Risk Managed Investment Strategies - خودرو بانک
C4 Therapeutics (CCCC) Rating Upgraded by Stephens & Co. with Price Target Increase | CCCC Stock News - GuruFocus
Inflation Data: Can C4 Therapeutics Inc. weather a recessionWeekly Stock Report & Stepwise Swing Trade Plans - خودرو بانک
Take Profit: Will C4 Therapeutics Inc. benefit from seasonality2025 Market WrapUp & AI Based Buy/Sell Signal Reports - khodrobank.com
Fulcrum Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
69,300 Shares: Travere Therapeutics Announces Major Employee Stock Grants with 4-Year Vesting Terms - Stock Titan
192,424 Shares in C4 Therapeutics, Inc. $CCCC Bought by Nuveen LLC - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 10, 2025 - BioSpace
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration - Investing News Network
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Market reaction to C4 Therapeutics Inc.’s recent newsMarket Performance Summary & Accurate Trade Setup Notifications - Newser
C4 Therapeutics Inc. Included in Top Momentum ScanJuly 2025 Sentiment & Weekly High Return Stock Opportunities - beatles.ru
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $8.00 Consensus Target Price from Brokerages - MarketBeat
C4 Therapeutics Inc. Breakout Confirmed by Volume MetricsQuarterly Profit Review & Community Verified Trade Signals - beatles.ru
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Is C4 Therapeutics Inc. forming a bottoming baseDollar Strength & AI Enhanced Execution Alerts - Newser
Can C4 Therapeutics Inc. recover in the next quarterEarnings Recap Summary & AI Driven Stock Movement Reports - Newser
Historical volatility pattern of C4 Therapeutics Inc. visualizedJuly 2025 Selloffs & AI Enhanced Trading Alerts - Newser
Machine Learning Models Forecast C4 Therapeutics Inc. UptickPortfolio Growth Summary & Daily Stock Momentum Reports - beatles.ru
Market Pulse: Will C4 Therapeutics Inc. benefit from seasonality2025 Momentum Check & Real-Time Stock Price Movement Reports - خودرو بانک
Earnings Miss: What is C4 Therapeutics Inc.’s book value per shareJuly 2025 News Drivers & Technical Buy Zone Confirmation - خودرو بانک
What is the dividend yield of C4 Therapeutics Inc.July 2025 Summary & Safe Entry Point Identification - خودرو بانک
Can C4 Therapeutics Inc. sustain its profitability2025 Trading Volume Trends & Verified Stock Trade Ideas - خودرو بانک
Can C4 Therapeutics Inc. weather a recessionQuarterly Risk Review & Weekly High Return Forecasts - خودرو بانک
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Oric Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
1.43%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):